Measles vaccination in Germany. The goal is to erradicate measles in Europe;Masernimpfung in Deutschland: Das ziel ist die elimination der masern in Europa

Monatsschrift fur Kinderheilkunde

Volumn 148, Issue 6, 2000, Pages 623-633

  Gerike, E ^a   Tischer, A ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MEASLES VACCINE;

ERADICATION THERAPY; EUROPE; GERMANY; HEALTH PROMOTION; HUMAN; MEASLES VACCINATION; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 0008630658     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001120050610     Document Type: Review

References (20)

1. Aickin R, Hill D, Kemp A (1994) Measles immunization in children with allergy to egg. Brit Med J 309:223-225
2. CDC (1997) Measles MMWR 46: No. RR-10, 23
3. CDC (1998) Progress toward global measles control and regional elimination. MMWR 47: 1049-1054
4. CDC (1998) Measles-United States 1997 MMWR 47: 273-276
5. Committee on Infectious Diseases, American Academy of Pediatrics (1997) Red Book, 24th ed, Peter G ed. Elk Grove Village, IL Measles: 344-357
6. Davidkin I, Valle M (1998) Vaccine - induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16: 2052-2057
7. Gerike E, Tischer A (1995) Aktuelle diagnostische Aspekte der Masernvirusinfektion. Diagnose & Labor 45: 109-126
8. Güris D, Mccready J, Watson JC, Athinson WL, Heath JL, Bellini WJ, Polloi A (1996) Measles Vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J 15: 1082-86
9. Kaplan JL, Daum RS, Smaron M, McCarthy CA (1992) Severe measles in immunocompromised patients. JAMA 267:1237-1241
10. Landen MG, Beller M, Funk E (1998) Measles outbreak in Juneau, Alaska, 1996: Implications for future outbreak control strategies. Pediatrics 102: E711
11. Liebert UG (1997) Measles virus infection of the central nervous system. Intervirology 40: 176-184
12. Molyneaux PJ, Mok JYQ, Burus SM, Yap PL (1993) Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus. J of Infection 27: 251-253
13. Pabst HF, Boothe PM, Carson MM (1999) A comparison of alternate immunization regimes for measles in vaccinated populations. Vaccine 17: 182-192
14. Peltola H, Heinone OP, Valle M, Pannio M, Vitranen M, Karanko V, Cantell K (1994) The elimination of indigenous measles, mumps and rubella from Finland by a 12 year, two-dose vaccination orogram. New Engl J Med 331: 1397-1402
15. Rota JS, Heath JL, Rota PA, King GE, Celma ML, Carabana J (1996) Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis 173: 32-37
16. Vaccine safety committee, Institute of Medicine (1994) Adverse events associated with childhood vaccines. National Academy Press, Washington, DC. Measles and mumps vaccines: 118-186
17. WHO (1996) Expanded Programme on Immunization (EPI). Meeting on Advances in Measles Elimination: Conclusions and recommendations. WER 71: 305-309
18. WHO, Regional Office for Europe (1997). EPI: 7th meeting of national programme managers. Berlin, 10-12 November 1977
19. WHO (1998) European Advisory Group of the Expanded Programme on Immunization, 14th meeting, London 17-19 January 1998
20. WHO (1998) Expanded Programme on Immunization (EPI). Progress towards elimination of measles in the Americas. WER 73: 81-85